Perrigo Company plc
$60.8K 12 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Vertical Pharmaceuticals, LLC
Vertical Pharmaceuticals, LLC reported $60,869.02 across General Payments, Research, and Ownership to 2,949 physicians and teaching hospitals across 2,949 transactions.
- $60.9K Below-median payer
- All-tracks total
- 2,949 Top quartile volume
- Transactions
- 2,949 Top quartile reach
- Recipients
- +$56.9K
- General Payments vs PY2023
Vertical Pharmaceuticals, LLC reported $60,869.02 across all CMS Open Payments tracks (General + Research + Ownership) to 2,949 physicians and teaching hospitals in Program Year 2024 - ranking #1305 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $60,869.02, averaging $20.64 per recipient.
Vertical Pharmaceuticals, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
11/100
Transaction volume
F
31/100
Physician reach
F
32/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vertical-pharmaceuticals-llc Vertical Pharmaceuticals, LLC
$60.9K · #1305/1,925 · 0.0% industry · PY2024
- TOT $60.9K
- RANK #1305
- SHARE 0.0%
- TXN 2,949
- RCP 2,949
- CAT 2
- GEN $60.9K
- ΔGEN +$56.9K
- TOP1 8.9%
- PY 2024
Volume peers
Nearest volume peer: Perrigo Company plc ($60.8K)
Vertical Pharmaceuticals, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Vertical Pharmaceuticals, LLC's CMS-reported General Payments increased by $56.9K (+1447.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: VERTICAL PHARMACEUTICALS, LLCPY2024: Vertical Pharmaceuticals, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,932.57
- PY2024
- $60,869.02
What the Data Shows for Vertical Pharmaceuticals, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Vertical Pharmaceuticals, LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $55.5K across 2,948 transactions, 91.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Vertical Pharmaceuticals, LLC's largest category was "Food and Beverage" at $55.5K - 91.1% of General Payments.
How Vertical Pharmaceuticals, LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $55.5K | 2,948 | 91.1% |
| Consulting Fee | $5.4K | 1 | 8.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,223.41 (10.2%) of $60,869.02 in this company's General Payments records across 1,898 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Vertical Pharmaceuticals, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Ann Childress
$5,400.00 across 1 reported transactions
- 2
Roshan Varghese Kurien
$223.20 across 17 reported transactions
- 3
Greg Rosenn
$214.45 across 12 reported transactions
- 4
Shakaibullah Sharief
$210.68 across 17 reported transactions
- 5
Landis Brook Stokum
$175.08 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Vertical Pharmaceuticals, LLC ranks #1305 of 1,925 by total payments (bottom 32% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,709 of 1,838 by HHI (bottom 7% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Biotissue Holdings Inc. : $2.1M total payments, HHI 90
- Kerecis Limited : $4.0M total payments, HHI 89
- Elite Orthopedics, Llc : $97.1K total payments, HHI 89
- Biosense Webster, Inc. : $3.2M total payments, HHI 89
- LEO Pharma Inc. : $3.1M total payments, HHI 88
- Medinc of Texas : $86.5K total payments, HHI 87
- Vertical Pharmaceuticals, LLC (this company) : $60.9K total payments, HHI 86
- Sight Sciences, Inc. : $1.0M total payments, HHI 85
- Astellas Pharma US Inc : $10.6M total payments, HHI 85
- Centrix Inc : $17.9K total payments, HHI 84
- Endologix LLC : $725.4K total payments, HHI 84
- Novartis Pharmaceuticals Corporation : $19.7M total payments, HHI 84
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Vertical Pharmaceuticals, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vertical Pharmaceuticals, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Vertical Pharmaceuticals, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ovesco Endoscopy USA, Inc.
$61.0K 62 recipients
Compare payment profiles
Lenoss Medical Inc
$61.1K 50 recipients
Compare payment profiles
Forma Medical
$61.1K 76 recipients
Compare payment profiles
Clarius Mobile Health Corp.
$60.4K 27 recipients
Compare payment profiles
Spirair, Inc.
$60.4K 219 recipients
Compare payment profiles
Put this to use
Vertical Pharmaceuticals, LLC ranks #1305 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Vertical Pharmaceuticals, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.